Cytokinetics, Incorporated · NASDAQ:CYTK
Cytokinetics — ESC Congress 2025
10 slides from Cytokinetics's conference presentation, Aug 31, 2025
Slide 1: Incidence and impact of atrial fibrillation in patients with obstructive HCM treated with aficamten
Incidence and impact of atrial fibrillation in patients with obstructive HCM treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials Ethan J. Rowin, MD1; Martin S. Maron, MD1; Iacopo Olivotto, MD2; Caroline J. Coats, MD, PhD3; Theodore P. Abraham, MD4; Michael E.
Slide 2: Disclosures & Acknowledgements
Disclosures & Acknowledgements Ahmad Masri reports research grants from Pfizer, Ionis, Attralus, Cytokinetics, and Janssen and consulting fees from BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Cytokinetics, Bristol Myers Squibb, Alnylam, Haya, Edgewise, Alexion, Akros, Prothena, BioMarin, Lexeo, Ast
Slide 3: Background
Background Atrial Fibrillation (AF): Aficamten: • Common in obstructive hypertrophic cardiomyopathy (oHCM)1 A next-in-class oral, selective CMI • Pre-CMI Era: ~2% per year and associated with morbidity1 Improvements in8: • SEQUOIA-HCM2: AF incidence – 2.9% placebo vs 2.8% Exercise LVOT Symptoms and
Slide 4: Background and Objective
Background • CMIs have distinct characteristics, binding sites, pharmacology, metabolism, and PK/PD relationship • Efficacy and safety should be studied at the individual CMI level OBJECTIVE To analyze rates of new-onset AF and the impact of AF on the efficacy and safety of aficamten over an extende
Slide 5: Methods
Methods STUDY DESIGN Patients with oHCM were treated with aficamten (5–20 mg) for ≥48 weeks in FOREST-HCM (global multicenter open-label extension study) N=173 following participation in REDWOOD-HCM or SEQUOIA-HCM OBSERVATION ANALYSIS No AF History: History of AF at the time The following outcomes f
Slide 6: Results
Results No AF History New Onset AF No further cardiac 136 (78.6%) 4/136 (2.9%) SAE or LVEF <50% 136 (78.6%) 4/136 (2.9%) LVEF <50% event N=173 1/4 participants 1/4 with oHCM AF History Recurrent AF 37 (21.4%) 10/37 (27.0%) 10/37 (27.0%) During 269 participant-years of follow-up with aficamten (media
Slide 7: Results: Observed vs Predicted New-Onset AF Rates
Results: Observed vs Predicted New-Onset AF Rates 1.5%/year The observed rate Observed Ratea of new-onset AF in aficamten studies was 3.6%/year, interaction p=0.1 similar or lower than that HCM-AF Riskb predicted by HCM-AF or CHARGE-AF risk 1.4%/year, calculators for the same interaction p=0.8 CHARG
Slide 8: Results: Clinical outcomes and AEs by on-treatment occurrences of AF
Results: Clinical outcomes and AEs by on-treatment occurrences of AF from baseline to Week 48 New-onset or recurrent No AF history or New-onset or recurrent AF episodes on new-onset AF during AF episodes vs no AF aficamten (n=14) treatment (n=132) on aficamten Between Efficacy (change from baseline)
Slide 9: Conclusions
• The annualized risk for new-onset AF during aficamten treatment was low (1.5%/year), occurring in just 4 participants • The observed incidence of new-onset AF was numerically lower than predicted rates based on the HCM-AF risk score, and similar to the rate by CHARGE-AF Conclusions • There was no
Slide 10: Simultaneous publication in Heart Rhythm
Simultaneous publication in Heart Rhythm